title: Modulation of tumor induction and progression of oncogenic K-ras-positive tumors in the presence of TGF- b1 haploinsufficiency.
abstract: Oncogenic K-ras is one of the most common genetic alterations in human lung adenocarcinomas. In addition, inactivation of clusters of tumor suppressor genes is required to bring about classical characteristics of cancer including angiogenesis as a prelude to invasion and metastasis. Transforming growth factor-beta (TGF-beta) 1 is a tumor suppressor gene that is implicated in lung cancer progression. Although in vitro studies have shown that TGF-beta1 and Ras pathways cooperate during tumorigenesis, the biology of interaction of TGF-beta1 and Ras has not been studied in in vivo tumorigenesis. We hypothesized that inactivation of TGF-beta1 in addition to oncogeneic activation of K-ras would lead to early initiation and faster progression to lung adenocarcinoma and invasion and metastasis. Heterozygous (HT) TGF-beta1 mice were mated with latent activatable (LA) mutated K-ras mice to generate TGF-beta1(+/+), K-ras LA (wild-type (WT)/LA) and TGF-beta1(+/-), K-ras LA (HT/LA) mice. Both HT/LA and WT/LA mice developed spontaneous lung tumors, but HT/LA mice progressed to adenocarcinomas significantly earlier compared with WT/LA mice. In addition, WT/LA adenocarcinomas had significantly higher angiogenic activity compared with HT/LA adenocarcinomas. Thus, while oncogenic K-ras mutation and insensitivity to the growth regulatory effects of TGF-beta1 is essential for initiation and progression of mouse lung tumors to adenocarcinoma, a full gene dosage of TGF-beta1 is required for tumor-induced angiogenesis and invasive potential. This study identifies a number of genes not previously associated with lung cancer that are involved in tumor induction and progression. In addition, we provide evidence that progression to invasive angiogenic lesions requires TGF-beta1 responsiveness in addition to Ras mutation.
authors: Cell and Cancer Biology Branch, National Cancer Institute, 9610 Medical Center Drive, Suite 300, Rockville, MD 20850, USA.
authors: Jyotsna
authors: J
authors: Pandey
authors: Sarah M
authors: SM
authors: Umphress
authors: Yang
authors: Y
authors: Kang
authors: Jerry
authors: J
authors: Angdisen
authors: Alena
authors: A
authors: Naumova
authors: Kim L
authors: KL
authors: Mercer
authors: Tyler
authors: T
authors: Jacks
authors: Sonia B
authors: SB
authors: Jakowlew
mesh_terms: D000230:Adenocarcinoma / Q000098:blood supply / Q000235:genetics / Q000378:metabolism*; D000818:Animals; D018450:Disease Progression; D011905:Genes, ras / Q000502:physiology*; D006579:Heterozygote; D008175:Lung Neoplasms / Q000098:blood supply / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D008810:Mice, Inbred C57BL; D008817:Mice, Mutant Strains; D009154:Mutation; D009389:Neovascularization, Pathologic; D020411:Oligonucleotide Array Sequence Analysis; D053773:Transforming Growth Factor beta1 / Q000235:genetics / Q000502:physiology*
chemical_list: D053773:Transforming Growth Factor beta1